

Vetter continues its successful performance at the 2021 CMO Leadership Award

18 February 2021 | News

Winning five core categories reaffirms Vetter as a trusted solution provider, particularly during globally challenging times



§ Vetter reaffirms its high performance in customer-critical aspects

§ Results reflect the positive experience of pharma and biotech companies in their daily work with the service provider – particularly during a pandemic

§ Winning five awards mirrors the company's core value of customer partnership'

Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), was granted the 2021 CMO Leadership Awards in five core categories – *quality, expertise, compatibility, capabilities, and service*. The award, now in its tenth year, was given by the leading trade press publication, Life Science Leader. Vetter was also the recipient of the award in a variety of categories in previous years.

“Yet again, Vetter is honored to be a winner of the CMO Leadership Awards as determined by our most important judges – our global customers,” said Vetter Managing Director Peter Soelkner. “This recognition is of particular importance given the challenging and turbulent times we are all experiencing with the global Covid-19 pandemic.” Carsten Press, Vetter’s Senior Vice President Key Account Management/Supply Chain Management/Marketing added, “Winning this award in five key categories is a direct reflection of what we strive to project to our customers. It further demonstrates our stable performance for them and especially their patients.”

Unlike other awards where an application process takes place, winners of the CMO Leadership Awards are chosen according to a customer ranking system. The basis for this is their hands-on experience with the service providers they have actually worked with. Using this method of validation means results are not able to be influenced in any manner. As such, the awards honor true customer performance and signify that winning companies have distinguished themselves through a leading level of support for the needs of their pharma and biotech customers.

“These past months reinforced the criticality of the services and partnership models provided by CDMOs to biopharma organizations of this size,” said Louis Garguilo, Chief Editor and Conference Chair, Outsourced Pharma. “In fact, much of the drug development and manufacturing industry was sustained by reliable outsourcing in the face of a horrible pandemic. That reliability was a result of constant dedication to customers, and perhaps, one attribute above all –

flexibility.”